Kyowa Hakko Kirin, AstraZeneca and subsidiaries are developing benralizumab (Fasenra™)—a humanised anti-interleukin-5 receptor alpha chain (IL-5Rα) monoclonal antibody—as a treatment of severe eosinophilic asthma and chronic obstructive pulmonary disease (COPD). Eosinophilia is a characteristic of certain asthma and COPD phenotypes and depletion of eosinophils has demonstrated therapeutic benefit. Benralizumab was recently approved by the US FDA as add-on maintenance therapy for patients with severe asthma who have an eosinophilic phenotype. This article summarizes the milestones in the development of benralizumab leading to this first approval for the treatment of severe eosinophilic asthma.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflict of interest
During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. A. Markham is a contracted employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.
Additional information about this Adis Drug Review can be found at http://www.medengine.com/Redeem/1CFCF0606E51C358.
- 3.AstraZeneca. Fasenra (benralizumab) receives US FDA approval for severe eosinophilic asthma [media release]. https://www.astrazeneca.com/. 15 Nov 2017.
- 4.AstraZeneca. AstraZeneca receives EU approval of Fasenra for severe eosinophilic asthma [media release]. https://www.astrazeneca.com/. 10 Jan 2018.
- 5.AstraZeneca. Fasenra receives approval in Japan [media release]. https://www.astrazeneca.com/. 19 Jan 2018.
- 6.AstraZeneca. FASENRA (benralizumab) injection, for subcutaneous use: US prescribing information. 2017. http://www.fda.gov. Accessed 8 Jan 2018.
- 7.BioWa Inc. BioWa, Inc. licenses anti IL-5 receptor antibody from Kyowa Hakko Kogyo Co., Ltd [media release]. http://www.biowa.com. 22 Mar 2005.
- 8.MedImmune Inc., BioWa Inc. MedImmune strengthens inflammatory disease pipeline through collaboration with Biowa [media release]. http://www.medimmune.com. 19 Dec 2006.
- 9.AstraZeneca. AstraZeneca enters option agreement with Kyowa Hakko Kirin for commercialisation of benralizumab in Japan [media release]. http://www.astrazeneca.com. 16 Jul 2015.
- 10.Kyowa Hakko Kirin. Kyowa Hakko Kirin enters agreement with AstraZeneca for development and commercialisation of benralizumab in Asia [media release]. http://www.kyowa-kirin.coms. 24 Mar 2017.
- 12.Newbold P, Liu H, Pham TH, et al. Modulation of inflammation by benralizumab in eosinophilic airway disease [abstract no. PA4902]. Eur Respir J. 2016;48(Suppl 60).Google Scholar
- 13.European Medicines Agency. CHMP summary of positive opinion for Fasenra. 2017. http://www.ema.europa.eu/. Accessed 8 Feb 2018.
- 15.Damera G, Brightling CE, Bleecker ER, et al. Pharmacodynamic effect of benralizumab on blood basophils and serum biomarkers in adults with chronic obstructive pulmonary disease and sputum eosinophilia [abstract no. P67]. Am J Respir Crit Care Med. 2015;191:A2711.Google Scholar
- 16.Eck S, Castro M, Sinibaldi D, et al. Benralizumab effect on blood basophil counts in adults with uncontrolled asthma [abstract no. P297]. Eur Respir J. 2014;44(Suppl 58).Google Scholar
- 18.Saito H, Yuji W, Kawai H, et al. Ascending single intravenous and subcutaneous dose studies of benralizumab in japanese healthy male volunteers: safety, tolerability, pharmacokinetics and pharmacodynamics [abstract no. P297]. Am J Respir Crit Care Med. 2015;191:A4270.Google Scholar
- 20.FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128–41.CrossRefPubMedGoogle Scholar
- 21.Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115–27.CrossRefPubMedGoogle Scholar
- 22.Ferguson GT, Mansur AH, Jacobs JS, et al. Functionality, reliability, and performance of an accessorized pre-filled syringe with home-administered subcutaneous benralizumab for adult patients with severe asthma [abstract no. A3194]. Am J Respir Crit Care Med. 2017;195:1.Google Scholar